Atria Wealth Solutions Inc. Reduces Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Atria Wealth Solutions Inc. reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.9% during the fourth quarter, Holdings Channel reports. The firm owned 36,425 shares of the medical research company’s stock after selling 321 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Edwards Lifesciences were worth $2,697,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Bowman & Co S.C. boosted its position in shares of Edwards Lifesciences by 1.2% during the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after purchasing an additional 148 shares in the last quarter. Mount Yale Investment Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 1.9% during the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after buying an additional 162 shares in the last quarter. JFS Wealth Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares in the last quarter. Seascape Capital Management grew its position in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after buying an additional 174 shares during the period. Finally, Cooper Financial Group increased its stake in shares of Edwards Lifesciences by 2.8% in the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock worth $479,000 after acquiring an additional 175 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

EW has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Truist Financial restated a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Morgan Stanley lifted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Robert W. Baird cut their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $79.95.

Insider Transactions at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock worth $2,002,829 in the last 90 days. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Down 2.0 %

Edwards Lifesciences stock opened at $73.25 on Friday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The stock has a fifty day moving average of $72.85 and a 200 day moving average of $69.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market cap of $43.20 billion, a PE ratio of 10.51, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.